Erasca, Inc. Form D Notices of Exempt Offering of Securities
Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.
- 2020-04-30: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2020-04-15; Total offering amount $374,536,960.
- 2019-03-11: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2018-10-30; Total offering amount $70,000,000.
- 2019-01-15: Federal exemption Rule 506(b); Types of securities offered Equity; Date of first sale 2018-10-30; Total offering amount $45,000,000.
| Filed | Federal exemption | Types of securities offered | Date of first sale | Total offering amount | Total amount sold | Total remaining to be sold | Investors who have already invested |
|---|---|---|---|---|---|---|---|
| 2020-04-30 | Rule 506(b) | Equity | 2020-04-15 | $374,536,960 | $125,405,005 | $249,131,955 | 46 |
| 2019-03-11 D/A | Rule 506(b) | Equity | 2018-10-30 | $70,000,000 | $58,278,287 | $11,721,713 | 41 |
| 2019-01-15 | Rule 506(b) | Equity | 2018-10-30 | $45,000,000 | $41,358,237 | $3,641,763 | 27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |